The growing prevalence of neurodegenerative diseases casts a profound shadow over global health, particularly as populations age. Conditions such as Alzheimer’s and Parkinson’s disease strip individuals of their cognitive abilities, motor function, and independence – impacting millions of families worldwide. The urgency to understand, diagnose, and treat these complex disorders has never been greater.

With this critical need in mind, we are proud to introduce Molecular Neurodegeneration Advances (MN Advances), a newly launched open-access journal dedicated to accelerating progress in neurodegeneration research. As a sister journal to the well-established Molecular Neurodegeneration, MN Advances provides a dynamic platform for groundbreaking studies that span molecular, cellular, and systems-level investigations.

What Makes MN Advances Unique?

MN Advances is committed to publishing high-quality, peer-reviewed research that illuminates the intricate mechanisms driving neurodegenerative diseases. Our scope is broad and inclusive, covering:

• Clinically and pathologically defined conditions such as Alzheimer’s disease, Parkinson’s disease, vascular dementia, and related disorders.
• Proteinopathies and molecular signatures, including tauopathies, synucleinopathies, and TDP-43 proteinopathies.
• Acute neurodegenerative events like stroke, traumatic brain injury, and spinal cord injury, which often trigger long-term degenerative processes.

Our mission is clear: to foster scientific communication that translates fundamental discoveries into improved patient care. From identifying biomarkers for early diagnosis to developing innovative therapeutic strategies, MN Advances aims to be at the forefront of research that changes lives.

Launching Our First Collection:

The Molecular Landscape of Neurodegeneration: Emerging Paradigms and Therapeutic Horizons

To mark this exciting beginning, MN Advances proudly announces its inaugural Collection: “The Molecular Landscape of Neurodegeneration: Emerging Paradigms and Therapeutic Horizons”. This Collection brings together cutting-edge research and expert perspectives on:

• Molecular drivers of disease progression: organelle dysfunction, protein misfolding, aggregation, myelin integrity, and clearance pathways.
• Neuroimmune interactions: the role of microglia, astrocytes, and inflammatory signaling.
• Genetic and epigenetic insights: multi-omics approaches, precision medicine, and environmental risk factors.
• Therapeutic innovation: novel drug targets, delivery systems, and regenerative strategies.

This Collection reflects our commitment to advancing knowledge and inspiring new approaches to diagnosis and treatment. We welcome submissions that fall within the scope of the Collection before 06 August 2026. Join Us in Shaping the Future of Neurodegeneration Research.

MN Advances is more than a journal – it’s a collaborative space for scientists, clinicians, and innovators worldwide. By embracing open access, we ensure that every published article is freely available, accelerating the dissemination of knowledge and fostering global collaboration.

We invite you to explore our aims and scope, our inaugural Collection, and consider MN Advances as your trusted venue for publishing impactful research. Together, we can illuminate the molecular pathways of neurodegeneration and pave the way toward effective therapies.

Discover the journal and the Collection here.